Leo Pharma has applied for expanded approval for eczema treatment in EU

At the same time as launching tralokinumab in the EU and US, Leo Pharma is also trying to expand the approved patient group for the treatment.
Photo: Leo Pharma/PR
Photo: Leo Pharma/PR
by mikkel aabenhus hemmingsen, translated by catherine brett

The EU Committee for Medicinal Products for Human Use (CHMP) has convened its monthly meeting, with a Danish treatment on the agenda.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading